Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer.

Autor: Tanegashima T; Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan., Shiota M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. shiota.masaki.101@m.kyushu-u.ac.jp., Terada N; Department of Urology, Miyazaki University, Miyazaki, Japan., Saito T; Department of Urology, Niigata Cancer Center Hospital, Niigata, Japan., Yokomizo A; Department of Urology, Harasanshin Hospital, Fukuoka, Japan., Kohei N; Department of Urology, Shizuoka General Hospital, Shizuoka, Japan., Goto T; Department of Urology, Kyoto University, Kyoto, Japan., Kawamura S; Department of Urology, Miyagi Cancer Center, Natori, Japan., Hashimoto Y; Department of Urology, Hirosaki University, Hirosaki, Japan., Takahashi A; Department of Urology, Hakodate Goryoukaku Hospital, Hakodate, Japan., Kimura T; Department of Urology, Jikei University, Tokyo, Japan., Tabata KI; Department of Urology, Kitasato University, Sagamihara, Japan., Tomida R; Department of Urology, Shikoku Cancer Center, Matsuyama, Japan., Hashimoto K; Department of Urology, Sapporo Medical University, Sapporo, Japan., Sakurai T; Department of Urology, Yamagata University, Yamagata, Japan., Shimazui T; Department of Urology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, Kasama, Japan., Sakamoto S; Department of Urology, Chiba University, Chiba, Japan., Kamiyama M; Department of Urology, University of Yamanashi Hospital, Chuo, Japan., Tanaka N; Department of Urology, and Department of Prostate Brachytherapy, Nara Medical University, Kashihara, Japan., Mitsuzuka K; Department of Urology, Tohoku University, Sendai, Japan., Kato T; Department of Urology, Kagawa University, Kagawa, Japan., Narita S; Department of Urology, Akita University, Akita, Japan., Yasumoto H; Department of Urology, Shimane University, Izumo, Japan., Teraoka S; Department of Urology, Tottori University, Yonago, Japan., Kato M; Department of Urology, Nagoya University, Nagoya, Japan., Osawa T; Department of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Japan., Nagumo Y; Department of Urology, University of Tsukuba Hospital, Tsukuba, Japan., Matsumoto H; Department of Urology, Yamaguchi University, Ube, Japan., Enokida H; Department of Urology, Kagoshima University, Kagoshima, Japan., Sugiyama T; Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan., Kuroiwa K; Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan., Kitamura H; Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan., Kamoto T; Department of Urology, Miyazaki University, Miyazaki, Japan., Eto M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Jazyk: angličtina
Zdroj: International journal of clinical oncology [Int J Clin Oncol] 2024 Dec 17. Date of Electronic Publication: 2024 Dec 17.
DOI: 10.1007/s10147-024-02681-2
Abstrakt: Background: In Japan, since 2014, new treatments such as androgen receptor signaling inhibitors and cabazitaxel have become applicable for metastatic castration-resistant prostate cancer (mCRPC), leading to dramatic changes in treatment options.
Objective: This study aims to evaluate the impact of recent advancements in treatment options on the overall survival (OS) of patients diagnosed with de novo metastatic castration-sensitive prostate cancer (mCSPC) in Japan.
Methods: A retrospective analysis was conducted on 2450 Japanese men diagnosed with de novo mCSPC between 2008 and 2018. Patients were stratified into two groups based on the period of diagnosis: an earlier period (2008-2013) and a later period (2014-2018). OS was compared between earlier and later periods using Kaplan-Meier analysis in total and propensity score matched subpopulation as well as risk-stratified subgroups.
Results: Patients diagnosed in the later period exhibited significantly improved OS compared to those diagnosed in the earlier period. The risk score, calculated based on ISUP grade group, LDH levels, and ALP levels, was a poor prognostic factor. In the later period, compared to the earlier period, there was no improvement in OS in the favorable-risk group, but a significant improvement was observed in the poor-risk group.
Conclusion: It was suggested that the introduction of novel androgen receptor signaling inhibitors and chemotherapy treatment regimens since 2014 has led to improved survival outcomes for patients with de novo mCSPC, particularly those with poor-risk profiles. The findings highlight the impact of recent advancements in treatment on the prognosis of patients with metastatic prostate cancer in Japan.
Competing Interests: Declarations. Conflict of interest: Masaki Shiota received honoraria from Janssen Pharmaceutical, AstraZeneca, Astellas Pharma, Sanofi, Bayer Yakuhin, and research funding support from Daiichi Sankyo. Naoki Terada received honoraria from Sanofi, Astellas Pharma, and Janssen Pharmaceutical. Takahiro Kimura received honoraria from Astellas Pharma, AstraZeneca, Bayer Yakuhin, Janssen Pharmaceutical, Sanofi, and Takeda Pharmaceutical. Hiroshi Kitamura reports consulting or advisory roles for Astellas Pharma, AstraZeneca, and Janssen Pharmaceutical; honoraria for Astellas Pharma, AstraZeneca, Janssen Pharmaceutical, Nippon Shinyaku, Sanofi, and Takeda Pharmaceutical; research funding for AstraZeneca and Takeda Pharmaceutical. Nobumichi Tanaka is affiliated with an endowed chair funded by Nihon Medi-Physics Co. Shintaro Narita received honoraria from Janssen Pharmaceutical, Astellas Pharma, and Bayer Yakuhin. Masatoshi Eto received honoraria from Ono Pharmaceutical, Takeda Pharmaceutical, Novartis Pharma, Pfizer, Bristol-Myers Squibb, Janssen Pharmaceutical, MSD, Merck Biopharma, AstraZeneca, and Eisai and research funding support from Bayer Yakuhin, Astellas Pharma, Ono Pharmaceutical, and Takeda Pharmaceutical.
(© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.)
Databáze: MEDLINE
Externí odkaz: